GlassScriptPhysician profile
Scott Robert Springer
NPI 1154075018
$95,287.73
in general payments reported to CMS, 2019-2025
10 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $4,314 · 2023: $38K · 2024: $31K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Travel and Lodging: $14K · Food and Beverage: $8,653 · Consulting Fee: $8,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,882.00 |
| Travel and Lodging | $14,102.03 |
| Food and Beverage | $8,652.72 |
| Consulting Fee | $8,336.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $69,283.07 | 2022-2025 | Epclusa, Biktarvy |
| Abbvie INC. | $20,936.56 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $2,439.65 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,606.29 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Novo Nordisk INC | $272.61 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $250.00 | 2025 | |
| Madrigal Pharmaceuticals | $223.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $159.46 | 2023-2025 | Ocaliva |
| Orexo US, INC. | $95.38 | 2024-2025 | Zubsolv |
| Celgene Corporation | $20.75 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.